Efficacy and safety of budesonide inhalation powder (Pulmicort Turbuhaler®) during 52 weeks of treatment in adults and children with persistent asthma

Journal of Asthma

Volumn 40, Issue 3, 2003, Pages 225-236

  Tinkelman, David G ^a   Bronsky, Edwin A ^b   Gross, Gary ^c   Schoenwetter, William F ^d   Spector, Sheldon L ^e  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b Intermountain Clinical Research   (United States)

^c Dallas Allergy & Asthma Center   (United States)

^d PARK NICOLLET CLINIC   (United States)

^e California Allergy and Asthma Medical Group   (United States)

Author keywords

Asthma; Budesonide; Oral corticosteroid sparing; Safety

Indexed keywords

ADRENALIN; AMINOPHYLLINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; METHYLPREDNISOLONE; PREDNISONE; SALBUTAMOL; TETRACOSACTIDE; THEOPHYLLINE;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; BRONCHITIS; CHILD CARE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLU LIKE SYNDROME; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INJURY; LARYNX DISORDER; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OTITIS MEDIA; PAIN; PHARYNGITIS; PHYSICAL EXAMINATION; POWDER; PRESCHOOL CHILD; RECURRENT DISEASE; RESPIRATORY TRACT INFECTION; RHINITIS; SINUSITIS; THEOPHYLLINE BLOOD LEVEL; THRUSH; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; ASTHMA; BUDESONIDE; CHILD; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; NEBULIZERS AND VAPORIZERS; POWDERS; TIME FACTORS;

EID: 0038547757     PISSN: 02770903     EISSN: None     Source Type: Journal    
DOI: 10.1081/JAS-120020186     Document Type: Article

References (27)

1. Djukanovic R, Roche WR, Wilson JW, Beasley CR, Twentyman OP, Howarth RH, Holgate ST. Mucosal inflammation in asthma. Am Rev Respir Dis 1990; 142(2):434-457.
2. Lemanske RF Jr, Busse WW. Asthma JAMA 1997; 278(22):1855-1873.
3. National Asthma Education and Prevention Program. Expert Panel Report II. Guidelines for the Diagnosis and Management of Asthma, NIH Publication No. 97-4051; National Heart, Lung, and Blood Institute; National Institutes of Health: Bethesda, MD, 1997.
4. Spector SL, Nicklas RA. Practice parameters for the diagnosis and treatment of asthma. J Allergy Clin Immunol 1995; 96(2):707-870.
5. Kamada AK, Szefler SJ. Glucocorticoids and growth in asthmatic children. Pediatr Allergy Immunol 1995; 6(3):145-154.
6. Pedersen S, O'Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy 1997; 52(39 suppl):1-34.
7. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med 1995; 332(13):868-875.
8. Brogden RN, McTavish D. Budesonide: an updated review of its pharmacological properties, and therapeutic efficacy in asthma and rhinitis. Drugs 1992; 44(3):375-407.
9. Johansson S-Å, Andersson K-E, Brattsand R, Gruvstad E, Hedner P. Topical and systemic glucocorticoid potencies of budesonide, beclomethasone dipropionate and prednisolone in man. Eur J Respir Dis Suppl 1982; 122:74-82.
10. Thorsson L, Edsbäcker S, Conradson T-B. Lung deposition of budesonide from Turbuhaler® is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J 1994; 7(10):1839-1844.
11. Wetterlin K. Turbuhaler: a new powder inhaler for administration of drugs to the airways. Pharm Res 1988; 5(8):506-508.
12. Kemp J, Wanderer AA, Ramsdell J, Southern DL, Weiss S, Aaronson D, Grossman J. Rapid onset of control with budesonide turbuhaler in patients with mild-to-moderate asthma. Ann Allergy Asthma Immunol 1999; 82(5):463-471.
13. Busse WW, Chervinsky P, Condemi J, Lumry WR, Petty TL, Rennard S, Townley RG. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J Allergy Clin Immunol 1998; 101(4 Pt 1):457-463.
14. Shapiro G, Bronsky EA, LaForce CF, Mendelson L, Pearlman D, Schwartz RH, Szefler SJ. Dose-related efficacy of budesonide administered via a dry powder inhaler in the treatment of children with moderate to severe persistent asthma. J Pediatr 1998; 132(6):976-982.
15. Pedersen S, Hanson OR, Fuglsang G. Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch Dis Child 1990; 65:308-310.
16. Persson G, Olsson B, Soliman S. The impact of inspiratory effect on inspiratory flow through Turbuhaler® in asthmatic patients. Eur Respir J 1997; 10:681-684.
17. Nelson HS, Bernstein IL, Fink J, Edwards TB, Spector SL, Storms WW, Tashkin DP. For the pulmicort Turbuhaler study group. Oral glucocorticosteroid-sparing effect of budesonide administered by Turbuhaler: a double-blind, placebo-controlled study in adults with moderate-to-severe chronic asthma. Chest 1998; 113 (5):1264-1271.
18. Osterman K, Carlholm M, Ekelund J, Kiviloog J, Nikander K, Nilholm L, Salomonsson P, Strand V, Venge P, Zetterström O. Effect of 1 year daily treatment with 400 μg budesonide (Pulmicort® Turbuhaler®) in newly diagnosed asthmatics. Eur Respir J 1997; 10(10):2210-2215.
19. Miyamoto T, Takahashi T, Nakajima S, Makino S, Yamakido M, Mano K, Nakashima M, Tollemar U, Selroos O. A double-blind, placebo-controlled steroid-sparing study with budesonide Turbuhaler in Japanese oral steroid-dependent asthma patients. Respirology 2000; 5 (3):231-240.
20. Aaronson D, Kaiser H, Dockhorn R, Findlay S, Korenblat P, Thorsson L, Kallen A. Effects of budesonide by means of the Turbuhaler on the hypothalamic-pituitary-adrenal axis in asthmatic subjects: a dose-response study. J Allergy Clin Immunol 1998; 101(3):312-319.
21. Pauwels RA, Löfdahl C-G, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, Ullman A. For the formoterol and corticosteroids establishing therapy (FACET) international study group. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337(20):1405-1411.
22. National Asthma Education and Prevention Program. Expert Panel Report. Guidelines for the Diagnosis and Management of Asthma - Update on Selected Topics 2002, NIH Publication No. 02-5075; National Heart, Lung, and Blood Institute; National Institutes of Health: Bethesda, MD, 2002.
23. The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 2000; 343(15):1054-1063.
24. Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med 2000; 343(15):1064-1069.
25. Källén B, Rydhstroem H, Aberg A. Congenital malformations after the use of inhaled budesonide in early pregnancy. Obstet Gynecol 1999; 93(3):392-395.
26. Ericson A, Källén B. Use of drugs during pregnancy - unique Swedish registration method that can be improved. Information from the Swedish Medical Products Agency 1999; 1:8-11.
27. Lipworth BJ, Jackson CM. Safety of inhaled and intranasal corticosteroids. Lessons for the new millennium. Drug Safety 2000; 23(1):11-33.